Compare YieldMax TSLA Option Income Strategy ETF (TSLY) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
YieldMax TSLA Option Income Strategy ETF vs Zimmer Biomet Holdings Inc — how do they compare? YieldMax TSLA Option Income Strategy ETF trades at $22.49, while Zimmer Biomet Holdings Inc trades at $94.73 (market cap $18.05B). The key difference: Zimmer Biomet Holdings Inc pays a 1.01% dividend while YieldMax TSLA Option Income Strategy ETF pays none, and Zimmer Biomet Holdings Inc is trading nearer its 52-week high, YieldMax TSLA Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.
| TSLY | ZBH | |
|---|---|---|
Sector | Income / Options Overlay | Health |
52-Week High | $48.25 | $104.26 |
52-Week Low | $20.49 | $79.58 |
Market Cap | — | $18.05B |
Enterprise Value | — | $25.11B |
Dividend Yield | — | 1.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TSLY trades at $22.79, up 3.17% over 24 hours, with a bullish technical signal supported by positive ADX readings. The ETF maintains a consistent weekly dividend payout strategy, with recent distributions ranging from $0.18 to $0.28 per share. However, key valuation and profitability ratios are unavailable, limiting fundamental clarity.
The outlook balances high income potential against capital erosion risks, as noted in recent analysis. Upside is constrained by Tesla's volatility dynamics, while dividend sustainability depends on option income generation. Investor caution is warranted given the lack of traditional financial metrics and mixed sentiment from financial media.
ZBH trades at $94.22, down 3.93% on the day, with a bearish technical signal but oversold RSI readings. Recent earnings beats and raised 2026 guidance support fundamentals, with revenue growth and strong gross margins. Leadership promotions aim to accelerate commercial transformation, while cash flow trends show operational strength.
The stock offers upside to the $104.88 consensus target, but faces headwinds from debt levels and competitive pressures. Near-term support at $92 is critical; a hold rating aligns with mixed analyst views. Earnings execution and procedure demand growth are key catalysts for valuation expansion.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About YieldMax TSLA Option Income Strategy ETF
TSLY is an actively managed ETF that seeks to provide high monthly income by employing a synthetic covered call strategy on Tesla, Inc. (TSLA). It does not own Tesla stock directly; instead, it uses a combination of call and put options to simulate long exposure while simultaneously selling call options to collect premiums. It is designed for income-focused investors who are willing to trade TSLA's potential upside for immediate, aggressive yield.
Read more on TSLY →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
